Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

NCT02431988 ↗

Phase 1 Completed 10 enrolled University College, London

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to administer novel cluster of differentiation antigen 19 (CD19) specific Chimeric Antigen Receptor T-cells (CAR19 T-cells) to patients with relapsed or resistant Diffuse Large B Cell Lymphoma (DLBCL) to assess the safety and efficacy of this strategy as a bridge to allogeneic transplantation.

Timeline

Start: 2016-06
Primary completion: 2020-02-02
Completion: 2022-03-21

Publications

Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR19 T-cells	Cell therapy	200000 cells/kg	—
Subject	CAR19 T-cells	Cell therapy	1e+06 cells/kg	—
Subject	CAR19 T-cells	Cell therapy	5e+06 cells/kg	—
Background	Cyclophosphamide	Other / unclassified	60 mg/kg	Intravenous
Background	Fludarabine	Small molecule	25 mg/m2	Intravenous

Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation

Summary

Timeline

Publications

Drugs

Indications